

A

α -carotene, 382

α -cryptoxanthin, 382

actinic elastosis, 468

AGE (advanced glycation end products) formation, 415, 469–476

 intervention strategies, 481–489

 receptors and target genes for end products, 476–481

aged skin/aging (chronological and photoaged).

See also cutaneous-aged skin; photoaged skin/photoaging

abnormalities, 347–350

assessments of

 mechanical properties, 365–367

 surface lipids, 363–365

assessments with biophysical instruments, 350–351

 color/erythema, 358–361

 microcirculation, 361–363

 producers of instruments, 368

 SC hydration, 354–356

 surface pH, 356–357

 TEWL, 351–353

DNA

 epithelial skin cancer, 83–85

 NER, 402–403

 oxidative damage and BER, 403–404

 repair capacity, 401

 repair system focus, 404–405

 stem cell manipulation, 505–506

 telomeres/telomerase, 504–505

 UVR-induced changes, 146–153, 395–396

environmental factors, 392–395

function alterations, 392

genes related to, 393, 394

growth factors, 496–501

histological features, 2–5

hormones

- lipogenesis, 517
- replacement therapy, 520–521
- skin morphology, effects on, 514–515
- skin permeability, 516
- wound healing, 516–517

influences on, 432–434

metabolism, 517–520

molecular-based changes, 8–18

outlook for problem-solving, 415–417

pathophysiology, 6–7

preventing with

- antioxidants, 273–286, 521–523
- carotenoids, 275, 283, 381–383, 522–523
 - vitamin C, 522
 - vitamin E, 522
- EAs, 383–385
- genistein, 275, 282
- green tea polyphenols, 523
- green tea/EGCG, 274, 277–279, 523
- hormone replacement therapy, 520–521
- nutrition, 378–386
- pomegranate, 274, 279–281
- resveratrol, 275, 282–283
- silymarin, 274, 281
- vitamin A, 378, 407
- vitamin B, 378–379, 435–438
- vitamin C, 275, 283–286, 378–379, 385–386, 438–441
- vitamin E, 275, 284–286, 378–379, 385–386

proteins

- AGE formation, protecting from, 415
- repairing, 413–415

repair systems, 397–400

- age-related damage, 406
- basement membranes, 413

reversing aging, 496–501

- ROS, 396–397
 - repairing, 413–415
 - senescence risk reduction, 393, 400, 405–406
 - theories, 431–432
 - turnover of
 - collagen, 408–410
 - epidermis, 407–408
 - HA, 410–413
 - UVR, 395–396
 - wound healing, 496–501
 - wrinkle formation, potentiating, 26–27
- AHAs (alpha hydroxy acids), 408
- American Academy of Dermatology
 - skin cancer and UVR, 158
 - sunscreen policies, 169–170
 - vitamin D and secondary tumors, 158
- American Academy of Pediatrics, 169
- angiogenesis
 - definition, 100
 - UVB-induced, 102–103
 - inhibition of, future perspectives, 106–107
 - molecular control of, 103–104
- antifibrotics, 59–70
- antioxidants, 273, 276–277, 521–523
 - carotenoids, 275, 283
 - genistein, 275, 282
 - green tea/EGCG, 274, 277–279, 523
 - pomegranate, 274, 279–281
 - resveratrol, 275, 282–283
 - silymarin, 274, 281
 - vitamin A, 378, 407
 - vitamin B, 378–379, 435–438
 - vitamin C, 275, 283–286, 378–379, 385–386, 438–441
 - vitamin E, 275, 284–286, 378–379, 385–386
- ascorbic acid derivatives, 440–441
- avobenzone sunscreen

- JCIA 2 UVA standard, 197
- SPF 15, 176
- SPF 50 continuous spray, 189
- ultimate sunscreen, 179
- US FDA-approved, 174–175
- US Federal Monograph approval, 165–166
- UVA effectiveness, 166, 193

B

- β-carotene, 382
- β-cryptoxanthin, 382
- basal cell carcinomas. *See* BCC
- base excision repair (BER), 403–404
- BCC (basal cell carcinomas). *See also* cancer (skin); epithelial skin cancer; SCC
 - environmental agents associated with developing, 81–82
 - health conditions associated with developing, 81–82
 - individuals at risk of developing, 82
 - phenotypes, diverse, 85–86
 - skin cancer statistics, 158
 - sonic hedgehog signaling defects, 86–88
- benzophenone-3 sunscreen
 - SPF 50 continuous spray, 189
 - ultimate sunscreen, 179
- BER (base excision repair), 403–404
- biophysical instrument aged skin assessments, 350–351
 - color/erythema, 358–361
 - microcirculation, 361–363
 - producers of instruments, 368
 - SC hydration, 354–356
 - surface pH, 356–357
 - TEWL, 351–353
- biophysics of SC (stratum corneum), 296–303
- blood and lymphatic vessels, 100–101
- botulinum toxin, 238–249, 249–252
- bovine collagen fillers, 250–251

C

- c-Jun amino terminal kinases (JNKs), 33, 34
- calcium hydroxylapatite fillers, 250–251
- cancer (skin). *See also* BCC; epithelial skin cancer; SCC
 - American Academy of Dermatology statistics, 158
 - vitamin D, UVR, and tumor cancer risks, 161–164
- carboxymethyl lysine (CML), 470, 473–474, 481–482
- carotenoids, 522–523
 - aging skin, influence on, 381–383
 - antioxidants, photoaging prevention, 275, 283
- CCN family proteins, 10–12
- ceramides, 296–303
- chemical peels
 - deep peels, 246
 - medium depth peels, 240, 244–246
 - superficial peels, 240–244
- chemodervation, botulinum toxin, 248–249, 249–252
- chronologically-aged skin. *See* aged skin/aging (chronological and photoaged)
- CIE (Commission Internationale de l'Éclairage), 358, 360
- cinoxate sunscreen, 174
- CML (carboxymethyl lysine), 470, 473–474, 481–482
- coenzyme Q10 (CoQ10), 453–454
- collagen, 28
 - producing, molecular-based changes, 8–18
 - turnover of, 408–410
 - types and effects on aging, 29–32
- color of skin. *See* skin color
- Commission Internationale de l'Éclairage (CIE), 358, 360
- connective tissue damage
 - cellular and biochemical changes, 6–7
 - histological features, 2–5
- CoQ10 (coenzyme Q10), 453–454
- corneocyte changes in SC (stratum corneum), 307–311
- corneodesmosomes, 303–306

cutaneous-aged skin. *See also* aged skin/aging (chronological and photodamaged); photoaged skin/photoaging
cancer from phenotypes from multipotential stem cells, 85–86
membrane signaling and repair processes, 32–37
prevention, future perspectives, 106–107
cytokines, 496–502, 506–507

D

dermabrasion, 247–248

dermis

collagen, 28

types and effects on aging, 29–32

elastin, 28

glycosamino-glycans, 28

gross aging changes, 28

desquamation of SC (stratum corneum), 303–307

dexpantenol, 436–438

DHA (docosahexaenoic acid), 383–384

dioxybenzone sunscreen, 174

DNA

epithelial skin cancer, 83–85

NER, 402–403

oxidative damage and BER, 403–404

repair capacity, 401

repair system focus, 404–405

stem cell manipulation, 505–506

telomeres/telomerase, 504–505

UVR-induced changes, 146–153, 395–396

docosahexaenoic acid (DHA), 383–384

dry skin and treatments with, 314–320

enzymes, 327–328

humectants/occlusive agents, 320–323

hydroxy acids, 325–327

inhibition of plasmin activity, 331

L-isomer of lactic acid, 330

ligands for nuclear hormone receptors, 329

- lipids, 323–324
- niacinamide, 331–333
- petroselinic and linoleic acids, 329
- phytosphingosine and derivatives, 330–331

E

- ECM (extracellular matrix) components, 28
 - MMPs, 40–41
 - inhibitors, 65, 68
 - TGF- β matrix repair, 44, 47
- EFA (essential fatty acid), 383–385
- EGCG/green tea, 274, 277–279
- eicosapentaenoic acid (EPA), 383–384
- elastin, 28
- elastotic material, 3–5
- electromagnetic spectrum of radiant energy, 171–173
- ensulizole sunscreen, 174
- enzymes, 327–328
- EPA (eicosapentaenoic acid), 383–384
- epidermis, turnover of, 407–408
- epithelial skin cancer. *See also* BCC; cancer (skin); SCC
 - cutaneous microenvironment factors, 91–92
 - environmental agents, 81–82
 - health conditions, 81–82
 - heredity factors, 83–85
 - individuals at risk, 82
 - photoaging as risk, 92
 - treatment, future prospects, 93–94
- ERKs (extracellular signal-regulated kinases), 34
- erythema/color of skin, assessments, 358–361
- essential fatty acids (EFAs), 383–385
- ethanolamine derivatives, 410
- ethylhexylmethoxycinnamate sunscreen, 193
- eumelanins, 255–259
- extinction coefficient, sunscreens, 177–178
- extracellular matrix (ECM) components, 28

MMPs, 40–41
inhibitors, 65, 68
TGF- β matrix repair, 44, 47
extracellular signal-regulated kinases (ERKs), 34

F — G

fish oils, 383–384

genistein, 275, 282

glycation. *See* AGE

glycolic acid, 408

peels, 241–242

glyoxal-lysine dimer (GOLD), 470, 471, 474

GOLD (glyoxal-lysine dimer), 470, 471, 474

green tea polyphenols, 523

green tea/EGCG, 274, 277–279, 523

growth factors

adjuncts to procedures, 501–502

aging skin, 496–501

hydrophilic molecules, skin penetration, 506–507

plant-derived, 503–504

risks associated with, 503

sources of, 502–503

stem cell manipulation, 505–506

telomeres/telomerase, 504–505

TGF- β (transforming growth factor- β), 8–10, 26

CCN family proteins, cooperation with, 10–12

targets for photodamage prevention/treatment, 57–69

wound healing, 42–48, 58, 61–62, 450

H — I

HA (hyaluronan), 410–413

heliodermatitis, 144

homosalate sunscreen

SPF 25, 190

SPF 25 spray, 190

- SPF 50 continuous spray, 189
- US FDA
 - approved, 174, 178
 - testing proposals, 198
- UVB effectiveness, 193–194
 - versus* padimate-O, 178
 - water resistant SPF method, 195
- hormones
 - lipogenesis, 517
 - replacement therapy, 520–521
 - skin morphology, effects on, 514–515
 - skin permeability, 516
 - wound healing, 516–517
- humectants/occlusive agents, 320–323
- hyaluronan (HA), 410–413
- hyaluronic acid fillers, 250–252
- hydroxy acids, 325–327. *See also* AHAs

J — L

JNKs (c-Jun amino terminal kinases), 33, 34

kinetin, 503–504

L-isomer of lactic acid, 330

lactic acid, 408

ligands for nuclear hormone receptors, 329

linoleic acid, 379–380

lipidomics of SC (stratum corneum), 296–303

lipids, 323–324, 363–365

lutein, 382, 383

lycopene, 382–383

lymphatic vessels

- and blood, in photoaging skin, 100–101

- UVB-induced impairment, 104–106

M

- MA (mevalonic acid), 408
- MAPKs (mitogen-activated protein kinases), 33, 34–35, 44
 - MMP inhibitors, 51, 55
- matrix metalloproteinases. *See* MMPs
- matrix proteinases, ovariectomy, effects on, 115–119
 - with UVA or UVB radiation, 127–133
- mechanical skin properties, assessments of, 365–367
- melanogenesis process, 255–266
- melanoma skin cancer, 158
- meradimate sunscreen, 174
- metabolism, 517–520
- methylglyoxal lysine dimer (MOLD), 470, 471, 473
- mevalonic acid (MA), 408
- Mexoryl XL sunscreen
 - US, use outside of, 175–176
 - UVA and UVB effectiveness, 193
- Mexoryl™ SX sunscreen
 - US FDA-approved, 165–166, 174, 175
 - UVA and UVB effectiveness, 193
- microcirculation of skin, assessments, 361–363
- microdermabrasion, 247
- mitogen-activated protein kinases (MAPKs), 33, 34–35, 44, 51, 55
- MMPs (matrix metalloproteinases), 0
 - basement membrane repair, 413
 - catabolism of key matrix proteins, 25–27
 - collagen turnover, 409
 - description, 37–41
 - inhibitors, 49–57
 - membrane signaling and aging repair processes, 32–37
 - molecular-based changes, 8–18
 - skin damage pathophysiology, 6–7
- MOLD (methylglyoxal lysine dimer), 470, 471, 473
- mtDNA, UVR-induced changes, 141, 150

N

- N*-acetylglucosamine (NAG), 412
- N*-methyl-L-serine (NMS), 412–413
- NA (niacinamide), 331–333, 407–408, 438
- NAG (*N*-acetylglucosamine), 412
- natural moisturizing factors (NMF), 312–314
- NER (nucleotide excision repair), 402–403
- niacin, 435–436, 437
- niacinamide (NA), 331–333, 407–408, 438
- nicotinic acid. *See* niacin
- NMF (natural moisturizing factors), 312–314
- NMS (*N*-methyl-L-serine), 412–413
- nuclear hormone receptors, 221–225
- nucleotide excision repair (NER), 402–403
- nutrition's influence on aging skin, 378
 - studies, 379–381
 - with carotenoids, 381–383
 - with EFAs, 383–385
 - with vitamin A, 378, 407
 - with vitamin B, 378–379
 - with vitamin C, 378–380, 385–386
 - with vitamin E, 378–379, 385–386

O

- octinoxate sunscreen
 - JCIA 2 UVA standard, 197
 - SPF 15, 176
 - SPF 25, 190
 - US FDA-approved, 174
- octisalate sunscreen
 - SPF 25, 190
 - SPF 50 continuous spray, 189
 - US FDA-approved, 174
- octocrylene sunscreen
 - SPF 50 continuous spray, 189
 - US FDA-approved, 174

- UVB effectiveness, 166
- octyl salicylate sunscreen, 193
- oleic acid, 383–384
- omega-3 PUFA, 384–385
- ovariectomy, effects
 - on matrix proteinases, 115–119, 127–133
 - on skin sagging/wrinkling and elasticity, 112–115
 - with or without UVB radiation, 116
 - with UVA or UVB radiation, 124–125
 - with UVA radiation, 119–120, 121
 - with UVB radiation, 120, 122–123
 - with UVB radiation, on three-dimensional structures, 125–127
- oxybenzone sunscreen
 - SPF 15, 176
 - SPF 25, 190
 - US FDA proposals, 198
 - US FDA-approved, 174
 - UVB effectiveness, 193

P — Q

- PABA (paraminobenzoic acid) sunscreen, 174
- padimate-O sunscreen
 - US FDA proposals, 198
 - US FDA-approved, 174
 - versus* homosalate, 178
- pantothenic acid, 436–437
- Parsol SLX sunscreen, 176
- petroselinic and linoleic acids, 329
- pH (skin) assessments, 356–357
- phenylethyl benzoate sunscreen
 - SPF 15, 176
 - SPF 50 continuous spray, 189
- pheomelanins, 255–259
- photoaged skin/photoaging. *See also* aged skin/aging (chronological and photoaged); cutaneous-aged skin
 - angiogenesis, UVB-based, 102–103

- blood and lymphatic vessels, involvement in, 100–101
- membrane signaling and repair processes, 32–37
- process mechanisms, 152
- wrinkles and fine lines, prevention/treatment, 49
- photocarcinogenesis, 158–161
- phytoene, 382
- phytofluene, 382
- phytosphingosine and derivatives, 330–331
- plasmin activity, inhibiting, 331
- polymethylmethacrylate fillers, 250–251
- pomegranate, 274, 279–281

R

- RA (retinoic acid). *See* vitamin A
- radiant energy, electromagnetic spectrum, 171–172
- RAGE (receptor for advanced glycation end products), 476–478, 483–484, 486, 488–489
- RCS (reactive carbonyl species), and AGEs, 469
- reactive oxygen species (ROS), 396–397
 - repairing, 413–415
- resveratrol, 275, 282–283
- retinoic acid (RA). *See* vitamin A
- retinoids. *See also* vitamin A
 - metabolism and binding proteins, 226–227
 - photoaged skin treatments
 - adapalene, 230
 - boosters, 232–233
 - esters, 231–232
 - isotretinoin, 230
 - retinaldehyde, 231
 - retinoic acid, 227–230
 - retinoid-like activities, 233–234
 - tazarotene, 230
 - receptors and nuclear hormone receptors, 221–225
- ROS (reactive oxygen species), 396–397, 413–415

S

salicylic acid peels, 242–243

SC (stratum corneum)

biophysics, 296–303

corneocyte changes, 307–311

corneodesmosomes, 303–306

decrease in quality and turnover rate, 399–400

desquamation, 303–307

dry skin and treatments with, 314–320

enzymes, 327–328

humectants/occlusive agents, 320–323

hydroxy acids, 325–327

inhibition of plasmin activity, 331

L-isomer of lactic acid, 330

ligands for nuclear hormone receptors, 329

lipids, 323–324

niacinamide, 331–333

petroselinic and linoleic acids, 329

phytosphingosine and derivatives, 330–331

hydration assessments, 354–356

lipidomics, 296–303

NMF, 312–314

normal and dry skin, 294

structure, 295–296

ceramides, 296–303

water profiles, 297

SCC (squamous cell carcinomas). *See also* BCC; cancer (skin);

epithelial skin cancer

cutaneous SCC, 88–91

environmental agents, 81–82

health conditions, 81–82

individuals at risk, 82

phenotypes, diverse, 85–86

skin cancer statistics, 158

SD alcohol 40, 189

- Se (selenium), 454–456
- senescence risk reduction, 393, 400, 405–406
- silymarin, 274, 281
- skin aging. *See* aged skin/aging (chronological and photoaged);
cutaneous-aged skin; photoaged skin/photoaging
- skin cancer. *See* BCC; epithelial skin cancer; SCC
- skin color
 - assessments, 358–361
 - measuring, 266–269
 - melanogenesis process, 255–261
 - interrupting and influencing, 261–266
 - parallel- and cross-polarized light differences, 254
 - whitening products, 269–271
- SMAD intracellular signaling proteins
 - membrane signaling and photoaging repair processes, 33, 35–36
- TGF- β
 - and matrix repair, 44–45
 - targets for prevention/treatment, 59, 62–65, 68
- sodium ascorbyl phosphate, 440–441
- solar elastosis, 145, 468
- squamous cell carcinomas. *See* SCC
- stratum corneum. *See* SC
- sulisobenzone sunscreen, 174
- sunburn cells, 144
- sunscreens
 - effectiveness, 164–169
 - extinction coefficient, 177–178
 - formulae development, 180
 - body sprays, 189–190
 - color cosmetics, 184–185
 - forms, 183–184
 - general, 181–183
 - hair care, 188
 - lip care, 187
 - skin care, 186–187
- immune system protection, 154–155

- organizations with policies concerning, 169–171
- product launches, 201–203
- testing
 - efficacy, 191
 - industry typical tests, 200–201
 - SPF, 191–196
 - UVA/UVB measurements/methods, 196–198
- ultimate sunscreen characteristics, 179–180
- US FDA proposals, 202–203
- US FDA-approved, 173–175, 201–202
- US, use outside of, 175–177
- surface lipids, assessments of, 363–365

T

- telomeres/telomerase, 504–505
- TEWL (transepidermal water loss) assessments, 351–353
- TGF- β (transforming growth factor- β), 8–10, 26
 - CCN family proteins, cooperation with, 10–12
 - targets for photodamage prevention/treatment, 57–69
 - wound healing, 42–48, 58, 61–62, 450
- TIMPs (tissue inhibitors of metalloproteinases), 36–37, 41, 44–45
 - natural MMP family, 49–52, 54–55
 - TGF- β targets for photodamage prevention/treatment, 63–64
- Tinosorb M and Tinosorb S sunscreens, 176
- titanium dioxide sunscreen
 - skin type differences, 184–185
 - US FDA-approved, 174–175
 - UVA and UVB effectiveness, 166, 193
- tocopherol compounds, 448–451
- transepidermal water loss (TEWL) assessments, 351–353
- transforming growth factor- β . *See* TGF- β
- trichloroacetic acid peels, 245–246
- trolamine salicylate sunscreen, 174

U

- ultraviolet radiation. *See* UVA radiation; UVB radiation; UVR

- Univul T 150 sunscreen, 176
- US (United States), sunscreens
 - FDA proposals, 202–203
 - FDA-approved, 173–175, 201–202
 - use outside of, 175–177
- UVA radiation. *See also* UVB radiation; UVR
 - ovariectomy, effects on matrix proteinases with UVA, 127–133
 - ovariectomy, effects on skin wrinkling
 - with UVA, 119–120, 121
 - with UVA or UVB, 124–125
 - sunscreens
 - effectiveness, 164–169, 193
 - organizations with policies, 169–171
 - testing, 196–198
- Uvasorb HEB sunscreen, 176
- UVB radiation. *See also* UVA radiation; UVR
 - angiogenesis, 102–104
 - lymphatic vessels, impairment induced by, 104–106
 - ovariectomy, effects on matrix proteinases with UVB, 127–133
 - ovariectomy, effects on skin wrinkling
 - with or without UVB, 116
 - with UVB, 120, 122–123
 - with UVB, on three-dimensional structures, 125–127
 - sunscreens
 - effectiveness, 164–169, 193
 - organizations with policies, 169–171
 - testing, 198–200
- UVR (ultraviolet radiation)
 - DNA, 395–396
 - electromagnetic spectrum, 171–173
 - immunosuppression, 437
 - photocarcinogenesis, 158–161
 - skin, effects on, 395–396
 - biological actions, 140–141
 - cancer, 157–158
 - histopathologic changes, 143–145

- immune system damage, 153–156
- molecular and genetic changes, 146–153
- penetration power from different UV regions, 142–143
- vitamin D and tumor cancer risks, 161–164

V

- vitamin A, 412, 441–445. *See also* retinoids
 - aging skin, influence on, 378, 407
- vitamin B, 378–379, 435–438
- vitamin C, 275, 283–286, 378–380, 385–386, 438–441, 522
- vitamin D, 161–164, 445–448
- vitamin E, 275, 284–286, 378–379, 385–386, 448–451, 522
- vitamin K, 451–453

W

- whitening products
 - formulating, 269–271
 - melanogenesis process, 255–261
 - interrupting and influencing, 261–266
- wound healing, 496–501
 - dexpanthenol, 438
 - fibroblasts, 477–478
 - hormones, 516–517
 - TGF- β (transforming growth factor- β), 42–48, 58, 61–62
 - vitamin D, 447
 - zinc, 457–458

X — Z

- xanthophylls lutein, 382, 383

- zeaxanthin, 382
- zinc (Zn), 456–458
- zinc oxide sunscreen
 - product forms, 183
 - US FDA-approved, 174–175
 - UVA and UVB effectiveness, 193